Mark Straley, Jan Egberts

Sep 28, 2015

Agendia has appointed Mark Straley its CEO, succeeding Jan Egberts, who has served as the interim CEO since October 2014.

Straley has more than 25 years of experience in developing and commercializing clinical diagnostics and laboratory services and most recently was president, anatomical pathology at Thermo Fisher Scientific. Prior to that, he was president and CEO of Metamark Genetics. Between 2005 and 2010, Straley was worldwide vice president of marketing, and then the worldwide president of Johnson & Johnson's Ortho Clinical Diagnostics.

Mark Straley, Jan Egberts

CareDx to Conduct Pharmacokinetic Testing in TC BioPharm's AML, MDS Cell Therapy Trial

UBS Initiates Coverage of Myriad Genetics With Neutral Rating

Quantum-Si, Canaccord Enter Agreement to Sell up to $75M in Common Stock in At-the-Market Offering

Taiwanese Spatial Proteomics Firm Syncell Closes $15M Series A Round

Biomemory Raises $18M in Series A Financing to Develop Enzymatic DNA Data Storage Technology